55 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 19346873 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | MCINTOSH III, TRAVISS C | 1693 | Non-Final OA | Oct 01, 2025 |
| 18592897 | HETEROCYCLIC COMPOUND AND USE THEREOF | HABTE, KAHSAY | 1624 | Non-Final OA | Mar 01, 2024 |
| 18390137 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | CARCANAGUE, DANIEL R | 1621 | Non-Final OA | Dec 20, 2023 |
| 18535781 | VEDOLIZUMAB FOR THE TREATMENT OF FISTULIZING CROHN'S DISEASE | HADDAD, MAHER M | 1641 | Non-Final OA | Dec 11, 2023 |
| 18557836 | METHOD FOR PRODUCING CELLS | NGUYEN, NGHI V | 1653 | Non-Final OA | Oct 27, 2023 |
| 18379047 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | LAU, JONATHAN S | 1693 | Non-Final OA | Oct 11, 2023 |
| 18550504 | INHIBITORS OF PLASMA KALLIKREIN | DEKARSKE, MADELINE MCGUIRE | 1622 | Non-Final OA | Sep 14, 2023 |
| 18550571 | PLASMA KALLIKREIN INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | Non-Final OA | Sep 14, 2023 |
| 18547809 | COMPOSITION AND METHODS FOR THE TREATMENT OF FABRY DISEASE | POPA, ILEANA | 1633 | Non-Final OA | Aug 24, 2023 |
| 18264150 | SUPPORT FIXTURE FOR CHROMATOGRAPHY COLUMNS | KRCHA, MATTHEW D | 1796 | Non-Final OA | Aug 03, 2023 |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | BUTTICE, AUDREY L | 1647 | Non-Final OA | Jun 13, 2023 |
| 18039137 | FLUID DELIVERY SYSTEM CONTAINER AND METHOD OF USE | FARRAR, LAUREN PENG | 3783 | Non-Final OA | May 26, 2023 |
| 18037834 | FLUID DELIVERY DEVICES AND METHODS THEREOF | LANGE, ERIC A | 3783 | Non-Final OA | May 19, 2023 |
| 18199216 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | KOSACK, JOSEPH R | 3991 | Final Rejection | May 18, 2023 |
| 18253425 | ADMINISTRATION OF STING AGONIST, CHECKPOINT INHIBITORS, AND RADIATION | HECK, BRYAN WILLIAM | 1643 | Non-Final OA | May 18, 2023 |
| 18316151 | POOLING DEVICE FOR SINGLE OR MULTIPLE MEDICAL CONTAINERS | ZIMBOUSKI, ARIANA | 3781 | Final Rejection | May 11, 2023 |
| 18029026 | PARATHYROID GLAND CELLS | BEHARRY, ZANNA MARIA | 1632 | Non-Final OA | Apr 11, 2023 |
| 18030901 | THERAPEUTIC AGENT FOR IMMUNE/INFLAMMATORY DISEASE | SZPERKA, MICHAEL EDWARD | 1641 | Non-Final OA | Apr 07, 2023 |
| 18022669 | INTERLEUKIN-2 MUTEINS AND USES THEREOF | GURLEY, JAMI MICHELLE | 1647 | Final Rejection | Feb 22, 2023 |
| 18160407 | LIBRARIES OF GENETIC PACKAGES COMPRISING NOVEL HC CDR1, CDR2, AND CDR3 AND NOVEL LC CDR1, CDR2, AND CDR3 DESIGNS | BOESEN, CHRISTIAN C | 1684 | Non-Final OA | Jan 27, 2023 |
| 18156279 | PREDICTING OUTCOME OF TREATMENT WITH AN ANTl-alpha4beta7 INTEGRIN ANTIBODY | HADDAD, MAHER M | 1641 | Final Rejection | Jan 18, 2023 |
| 18082799 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | HAVLIN, ROBERT H | 1626 | Non-Final OA | Dec 16, 2022 |
| 17995615 | NEEDLE CONNECTORS AND MODULAR NEEDLE CONNECTORS FOR MULTI-DOSE DRUG DELIVERY DEVICES AND METHODS THEREOF | GRASMEDER, SARAH DYMPNA | 3783 | Non-Final OA | Oct 06, 2022 |
| 17916621 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | WEN, SHARON X | 1641 | Non-Final OA | Oct 03, 2022 |
| 17916441 | ADAMTS13 VARIANT, COMPOSITIONS, AND USES THEREOF | ROBINSON, HOPE A | 1652 | Final Rejection | Sep 30, 2022 |
| 17995198 | Subcutaneous Port With Locking Member | STIGELL, THEODORE J | 3783 | Non-Final OA | Sep 30, 2022 |
| 17916467 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | REILLY, SOPHIA JANE | 1627 | Non-Final OA | Sep 30, 2022 |
| 17906433 | IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF | BECKHARDT, LYNDSEY MARIE | 1613 | Non-Final OA | Sep 15, 2022 |
| 17767663 | MODIFIED HETERO NUCLEIC ACIDS | ZAHORIK, AMANDA MARY | 1636 | Final Rejection | Jul 08, 2022 |
| 17778611 | T-CELL MASTER CELL BANK | ZHU, JIANJIAN | 1631 | Final Rejection | May 20, 2022 |
| 17745770 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | KOLKER, DANIEL E | 1645 | Final Rejection | May 16, 2022 |
| 17773535 | METHODS FOR DETECTING OLIGONUCLEOTIDES | SISSON, BRADLEY L | 1682 | Final Rejection | Apr 29, 2022 |
| 17769452 | METHOD FOR EVALUATING DRUG TOXICITY | MARTIN, RACHEL E | 1657 | Non-Final OA | Apr 15, 2022 |
| 17760908 | NUCLEIC ACID COMPLEX | SHIN, DANA H | 1635 | Final Rejection | Mar 16, 2022 |
| 17672748 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | Feb 16, 2022 |
| 17285397 | NUTRITION COMPOSITION | BAUER, NICOLA MARIA | 1621 | Non-Final OA | Jan 14, 2022 |
| 17622580 | TRANSFECTION METHOD | MEJIAS, SAMANTHA LEE | 1618 | Final Rejection | Dec 23, 2021 |
| 17622044 | ADENO-ASSOCIATED VIRUS PURIFICATION METHODS | SIFFORD, JEFFREY MARK | 1671 | Non-Final OA | Dec 22, 2021 |
| 17556857 | PURIFICATION OF FVIII FROM PLASMA USING SILICON OXIDE ADSORPTION | ESPINOSA, CLAUDIA EDILMA | 1654 | Non-Final OA | Dec 20, 2021 |
| 17554539 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | ESPINOSA, CLAUDIA EDILMA | 1654 | Non-Final OA | Dec 17, 2021 |
| 17618080 | METHOD FOR PRODUCING RENAL INTERSTITIAL CELL | SPENCE, JENNIFER SUZANNE | 1633 | Final Rejection | Dec 10, 2021 |
| 17596421 | METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY | FAUST, AMBER KATHLEEN | 1643 | Final Rejection | Dec 09, 2021 |
| 17596422 | ANTIBODY PURIFICATION METHODS AND COMPOSITIONS THEREOF | EDWARDS, JESSICA FAYE | 1657 | Final Rejection | Dec 09, 2021 |
| 17491813 | EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS | PETRASH, HILARY ANN | 1644 | Non-Final OA | Oct 01, 2021 |
| 17427222 | METHOD FOR DETECTING CELLS | GAO, ASHLEY HARTMAN | 1678 | Final Rejection | Jul 30, 2021 |
| 17423063 | HTT REPRESSORS AND USES THEREOF | VYAS, KEYUR ANILKUMAR | 1637 | Non-Final OA | Jul 14, 2021 |
| 17286334 | METHOD FOR ACTIVATION/PROLIFERATION OF T CELLS | EBBINGHAUS, BRIANA NOEL | 1632 | Final Rejection | Apr 16, 2021 |
| 17284291 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | SZPERKA, MICHAEL EDWARD | 1641 | Final Rejection | Apr 09, 2021 |
| 17279228 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | D' AMBROSIO, THEA | 1654 | Non-Final OA | Mar 24, 2021 |
| 17169835 | SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS | STEELE, AMBER D | 1658 | Non-Final OA | Feb 08, 2021 |
| 17264720 | FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE | COFFA, SERGIO | 1658 | Final Rejection | Jan 29, 2021 |
| 17263675 | METHOD FOR PRODUCING CD3-POSITIVE CELL | SHUPE, ELIZABETH A | 1643 | Non-Final OA | Jan 27, 2021 |
| 17041783 | SUBCUTANEOUS DOSING OF ANTI-CD38 ANTIBODIES | BENAVIDES, JENNIFER ANN | 1675 | Non-Final OA | Sep 25, 2020 |
| 16817671 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | KIM, YUNSOO | 1641 | Non-Final OA | Mar 13, 2020 |
| 14407174 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | HAVLIN, ROBERT H | 1626 | Final Rejection | Dec 11, 2014 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial